Research

Hetero prides itself for being one of the few pharmaceutical organisations that thrives on a robust Research and Development program. In fact, it is the mainstay of our continued success. We started investing in R&D as early as 1995, which gave us a head start for developing an expansive basket of products to meet diverse market requirements across the globe. Also, our extensive focus on R&D helped us transcend API & Formulation research to successfully expand our capabilities into the realm of Biosimilars.


Spearheaded by more than 500 top-notch scientists,our R&D team excels at developing generics, difficult-to-make & complex APIs (Active Pharmaceutical Ingredients), formulations, Novel Drug Delivery Systems (NDDS), New Chemical Entities (NCEs) and Biosimilar products besides consistently evolving with a sustainable pipeline of products.